ClinicalTrials.gg
CompletedNCT01195454Updated Oct 31, 2011

Euglycemic Clamp Dose-response Study Comparing a New Insulin Glargine Formulation With Lantus®

A Phase 1 interventional study of Insulin glargine (HOE901) and Insulin glargine (HOE901) in Type 1 Diabetes Mellitus, sponsored by Sanofi. Completed at 1 site in Germany. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-10-31.

Sponsored by Sanofi · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 — none open to participants now, none under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus, Type 1.

Enrollment
54th of 66
24 · median 73
Started
2010
with 2 others
Phase 1
14 of 66
none open now
Registered
23rd of 66
by date
Lead sponsor
24 of 66
Sanofi

Among the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1, this one is the 54th largest by enrollment, is one of 3 that started in 2010, is one of 14 in phase 1, and was the 23rd registered.

Diabetes Mellitus, Type 1

3,757 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

None of the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 is open now. The open studies under Diabetes Mellitus, Type 1, anywhere →

About Insulin Glargine

Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 416 Diabetes Mellitus, Type 1 studies recruiting now, 129 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 66 studies testing Insulin Glargine in Diabetes Mellitus, Type 1 as a file.
02

Study summary

Primary Objective:

  • To assess the total metabolic effect ratios of a new insulin glargine formulation versus Lantus®

Secondary Objectives:

  • To assess the exposure ratios of a new insulin glargine formulation versus Lantus®
  • To compare the duration of action of a new insulin glargine formulation versus Lantus®
  • To explore the dose response and dose exposure relationship of a new insulin glargine formulation
  • To assess the safety and tolerability of a new insulin glargine formulation
Read the detailed description

The study period for one patient is one month in average and it can last up to 11 weeks broken down as follows:

  • Screening: 3 to 28 days
  • Treatment period: 1 to 4 days: 2 days (1 overnight stay)
  • Washout period: 5 to 18 days (preferentially 7 days between consecutive dosings)
  • End of study: 1 day after the last dosing
03

Conditions studied

  • Type 1 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female subjects with diabetes mellitus type 1 for more than one year,
  • Total insulin dose of \<1.2 U/kg/day,
  • Glycohemoglobin () ≤ 9.0%,
  • Fasting negative serum C-peptide (\< 0.3 nmol/L),
  • Stable insulin regimen for at least 2 months prior to study,
  • Normal findings in medical history and physical examination (cardiovascular system, chest and lungs, thyroid, abdomen, nervous system, skin and mucosae, and musculo-skeletal system), vital signs, (ECG) and safety lab,
  • Women of with negative pregnancy test and use of a highly effective method or women with confirmed status.

Exclusion criteria

Exclusion criteria:

  • Any history or presence of cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic (apart from diabetes mellitus type 1), hematological, neurological, psychiatric, systemic (affecting the body as a whole), ocular, gynecologic (if female), or infectious disease; any acute infectious disease or signs of acute illness,
  • More than one episode of severe hypoglycemia with seizure, coma or requiring assistance of another person during the past 6 months,
  • Frequent severe headaches and / or migraine, recurrent nausea and / or vomiting (more than twice a month),
  • Symptomatic hypotension (whatever the decrease in blood pressure), or asymptomatic postural hypotension defined by a decrease in SBP equal to or greater than 20 mmHg within three minutes when changing from the supine to the standing position,
  • Presence or history of a drug allergy or clinically significant allergic disease,
  • Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol,
  • Pregnant or breast feeding women,
  • Any medication (including St John's Wort) within 14 days before inclusion, or within 5 times the elimination half-life or pharmacodynamic half-life of that drug, whichever the longest and regular use of any medication other than insulins in the last month before study start with the exception of thyroid hormones, lipid-lowering and antihypertensive drugs, and, if female, with the exception of hormonal or menopausal hormone replacement therapy; any vaccination within the last 28 days,
  • Positive reaction to any of the following tests: surface (HBs Ag) antigen, antihepatitis B core antibodies (anti-HBc Ab) if compound having possible immune activities, anti- virus (anti-HCV2) antibodies, anti- 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab),
  • Known to insulin glargine and ,
  • Any history or presence of deep leg vein thrombosis.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Insulin glargine / New insulin glargine formulation

    * Period 1: Insulin glargine * Period 2: New insulin glargine formulation * Period 3: New insulin glargine formulation * Period 4: New insulin glargine formulation Duration of treatment: 1 day at each period

    Drug: Insulin glargine (HOE901)

Interventions

06

What researchers measure

Primary outcomes

  1. The area under the body weight standardized glucose infusion rate curve (GIR) within 36 hours (GIR-AUC0-36)

    Time frame: 36 hours (D1 to D2) in all four treatment periods

Secondary outcomes

  1. The area under the insulin glargine concentration curve within 36 hours (INS-AUC0-36) -

    Time frame: 36 hours (D1 to D2) in all four treatment periods

  2. Time to 50% of the GIR-AUC0-36 (T50%-GIR AUC0-36)

    Time frame: 36 hours (D1 to D2) in all four treatment periods

  3. Time to 50% of INS-AUC0-36 (T50% INS-AUC0-36)

    Time frame: 36 hours (D1 to D2) in all four treatment periods

  4. Duration of blood glucose control (time to elevation of smoothed blood glucose profile above clamp level and to elevation above different pre-specified blood glucose levels)

    Time frame: 36 hours (D1 to D2) in all four treatment periods

  5. Maximum smoothed body weight standardized glucose infusion rate GIRmax, and time to GIRmax (GIR-Tmax)

    Time frame: 36 hours (D1 to D2) in all four treatment periods

  6. Maximum insulin concentration INS-Cmax, and time to Cmax (INS-Tmax)

    Time frame: 36 hours (D1 to D2) in all four treatment periods

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Berlin, Germany
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2010, a primary completion of Nov 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2010
First posted
Sep 6, 2010
Start
Aug 2010
Primary completionActual
Nov 2010
CompletionActual
Dec 2010
Last update
Oct 31, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01195454
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Sep 6, 2010
Start date
Aug 2010
Primary completion
Nov 2010
Completion
Dec 2010
Last update
Oct 31, 2011

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion